
    
      The primary study endpoint is the change in percent measurements of the pre-to-post apheresis
      LDL measurements between the approved H.E.L.P. system and the modified H.E.L.P. system. The
      secondary study endpoints are clinical lab profiles and device parameters analyzed at
      specific time points throughout the study.
    
  